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Introduction, Michael Farthing1
As United European Gastroenterology (UEG) cele-
brates 25 years as a major provider of international
conferences, postgraduate education, a leading commu-
nicator of discovery science and an advocate of high-
quality clinical practice across Europe, it seemed right
to review our achievements in gastroenterology and
hepatology.
In 2014, UEG commissioned a survey of the impact
of gastrointestinal (GI) and liver disease in Europe with
the intention that this should guide future healthcare
planning and research. The presentations in the 25th
UEG Week Anniversary Session have updated that
work, focusing on the major advances that have been
made in the treatment of inflammatory bowel disease
(IBD), Hepatitis C virus infection (HCV), Helicobacter
pylori (H. pylori), gastro-oesophageal reflux disease
(GERD), the treatment of childhood diarrhoea and
the diagnosis and treatment GI cancer. The extraordin-
ary technical advances that have been made in GI
endoscopy and laparoscopic surgery are also discussed.
In addition to the impact survey, UEG also under-
took a scenario planning exercise to further understand
the range of possibilities for the delivery of care in GI
and liver disorders. During the final part of the anni-
versary session we, like a fortune-teller, gazed into a
‘crystal ball’ and imagined how healthcare profes-
sionals in our disciplines would deal with the challenges
ahead.
Antibodies in inflammatory bowel diseases,
Julian Pane´s2
The introduction of the monoclonal antibodies (MAbs)
in the treatment of IBD represented a true revolution.
MAbs have provided new effective and safe modes of
therapy, but also brought to the field of IBD new para-
digms for drug dosing, the redefinition of therapeutic
targets, and completely changed the design of drug
development programmes.
Initial studies with infliximab for treatment of
Crohn’s disease or ulcerative colitis generated enthusi-
asm for its efficacy, but it became apparent that some
patients did not respond or lost response during therapy.
One of the early reasons identified for this problem was
the development of anti-drug antibodies. It became clear
that the pharmacokinetics of MAbs is complex, with
many factors, in addition to immunogenicity, affecting
drug clearance and drug concentration at target tissue,
including leakage of antibody into the gut lumen, target
abundance, and drug degradation by metalloproteinases
at sites of inflammation.
The development of therapeutic MAbs has also
introduced the use of objective measures of disease
activity and severity, both for patient selection and as
an outcome measure. It is also informing the selection
of therapeutic targets in studies and clinical practice,
showing that endoscopic remission is associated with
superior long-term clinical outcomes.
Hepatitis C virus: Discovery and extinction,
Michael Manns3
HCV causes chronic hepatitis which might result in
liver cirrhosis, hepatocellular carcinoma, liver trans-
plantation or death. Globally, more than 100 million
people are chronically infected. The discovery of HCV
in 1989 led to the development of hepatitis C antibody
testing (anti-HCV) and subsequently HCV RNA meas-
urement, viral genotype and subtype determination.
This blood-borne infection was caused by blood and
blood products until anti-HCV blood product screen-
ing was introduced in 1990. At present, major risk fac-
tors are unsafe injection drug use and unsterile medical
procedures, in particular in countries with a high HCV
prevalence. The interplay between basic research and
clinical medicine led to the development of diagnostic
tests and HCV therapies that for the first time enabled a
cure of a chronic viral infection in man. Milestones of
this development are virus discovery, the establishment
of diagnostic tests, the identification of the HCV life
cycle and the development of an in vitro replicon
system that paved the way towards direct-acting anti-
viral agents (DAAs). Therapeutic developments had
already started in 1986 with the use of recombinant
interferon alfa when the disease was still called non-
A, non-B hepatitis and the virus had not been dis-
covered. Cure rates gradually improved over the years
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due to higher doses and longer durations of interferon
alfa, the addition of ribavirin, the use of long-acting
pegylated interferons (PEG-IFN) and finally DAAs.
Three different classes of DAAs target three different
steps in the HCV replication cycle: the NS3/4 protease,
the HCV polymerase and the NS5A protein, which is
unique for HCV infection. In 2014, the first all-oral
interferon-free regimen became available and in 2017
combinations of two or three DAAs have allowed for
the cure of HCV infection close to 100% for all geno-
types and all patient populations, including decompen-
sated liver disease in 8–16 weeks and almost without
any side effects. As of today HCV is still a major global
health burden. The discovery of HCV and the subse-
quent development of diagnostic tests and HCV thera-
pies was a masterpiece of modern translational
medicine that should facilitate global HCV eradication.
Helicobacter pylori: The Nobel bug,
John Atherton4
The landmark description of H. pylori by Robin Warren
and Barry Marshall in their letters to the Lancet in 1983
heralded a revolution in the understanding and practice
of gastroenterology. Most peptic ulceration – particu-
larly duodenal ulceration – is an infectious disease
caused by a bacterium that is acquired in childhood
and carried lifelong. A simple combination of antibiotics
(usually with a proton pump inhibitor) not only heals
ulcers but prevents their recurrence: it cures the disease.
Even more significantly, gastric adenocarcinoma – until
recently the second biggest cancer killer in the world – is
also largely an infectious disease. AsH. pylori prevalence
is falling so, dramatically, is the incidence of gastric
cancer. This is one of the biggest public health successes
of our generation.
However, all is not perfect. H. pylori has lived in our
stomachs at least since humans emerged from Africa,
and most likely throughout our evolution. As we have
co-evolved with it, our physiology and immunology
have adapted to its presence. Without it, our stomachs
are, on average, more acidic and H. pylori-free humans
more frequently develop complications of GERD –
Barrett’s oesophagus and oesophageal adenocarcin-
oma. H. pylori also stimulates a regulatory immune
response and the lower level of this in H. pylori-free
individuals may explain why some allergic diseases,
notably childhood asthma, are more common in those
who are H. pylori negative. Avoidance of gastric cancer
is likely to greatly outweigh these considerations: an
H. pylori-free individual is likely to be a healthier indi-
vidual – but not one who is at reduced risk of all
diseases.
Endoscopy: A technical revolution,
Paul Fockens5
The impact of the advances in flexible gastrointestinal
endoscopy in the past 25 years on patients with GI
disease, has been larger than any other development in
our specialty. Thinking back, patients with acute ulcer
bleeding were scoped to identify the cause of bleeding
and then went for surgical therapy. Nowadays endoscopy
is both the first and second line of treatment in any ulcer
bleeding. Patients with a dysplastic Barrett’s oesophagus
all used to go for esophageal resection because of ‘invis-
ible’ cancers in 40%. Now they are diagnosed and treated
endoscopically with mucosal resection and/or ablation.
Stones in the common bile duct (CBD) were an indica-
tion for open surgical exploration, a technique that in
2017 hardly any surgeon still masters and ERCP (endo-
scopic retrograde cholangio-pancreatography) is taking
care of 99% of CBD stones now. Another bright example
is that large flat colonic polyps were either missed (and
became interval cancers) or went for surgical resection
with considerable morbidity and mortality. In 2017,
we detect them and more than 90% can be treated
endoscopically. Gastroenterology and hepatology are
larger than GI endoscopy alone, but high definition GI
endoscopy has become a most important technique for
detection and treatment of early neoplastic changes in the
GI tract and has replaced surgery in multiple other areas,
reducing the burden for our patients.
Treating diarrhoea in children: A global
life-saver, Sibylle Koletzko6
Diarrhoea is the cause of death in 1 out of 10 children
dying under the age of 5 worldwide. In 2015, diarrhoea
killed 1400 young children per day, or 526,000 per year
(UNICEF, One is too many. Ending child deaths from
pneumonia and diarrhoea, November 2016). Diarrhoea
is most deadly in the poorest places in the world such as
sub-Saharan Africa and South Asia. Many children
could be saved through rather basic interventions.
The younger the child, the greater is the risk that fluid
and electrolyte losses will lead to health-threatening
dehydration. Fluid losses from diarrhoea and vomiting
can be as high as three times the circulating blood
volume. The type of dehydration – isotonic, hypotonic
or hypertonic – is independent of the causative organism
(viral or bacterial), and in all three situations treatment
with oral rehydration solution (ORS) is safe and effective.
ORS was developed after the discovery of the coupled
co-transport of sodium and glucose in the enterocytes.
In the presence of glucose or galactose, sodium is more
effectively taken up from the intestinal lumen by the
sGLT1 transporter. Water then passively follows the
1054 United European Gastroenterology Journal 5(7)
sodium influx. Since 2004, UNICEF and the World
Health Organization have promoted low-osmolarity
ORS and zinc, in addition to continued feeding, but
little progress has been made in the broad implementa-
tion over the last decade, with only 2 out of 5 affected
children being treated with ORS. Besides improving
accessibility, particularly in rural areas of poor countries,
education of health care providers and parents is crucial
for implementation of good diarrhoea management.
Preventive measure such as providing clean water, pro-
moting breast feeding and a vaccination programme
against rotavirus infection will further decrease the
deadly burden of diarrheal diseases.
Gastrointestinal cancer treatment goes
personal, Thomas Seufferlein7
For many years, 5-fluorouracil (5-FU)-based chemo-
therapy was the mainstay for the treatment of GI
tumours, achieving moderate results. Over recent
years, this has substantially changed. New chemother-
apeutic agents have been introduced. Furthermore,
based on data from signal transduction research, so-
called targeted agents have been developed that address
specific properties of a given tumour such as the
Epidermal Growth Factor receptor or the human
epidermal growth factor receptor 2. Now, there is a
plethora of drugs that target the majority of signalling
network components in cancer. Large-scale tumour
sequencing has also developed rapidly over the past
years and allows us to identify the molecular alterations
in a given tumour. These approaches revealed that
apart from the conventional pathological classification
there is a novel molecular classification of cancer. Using
such a classification, a whole cancer entity such as pan-
creatic or colorectal cancer is reclassified into subgroups
according to their specific molecular profile. This allows,
in principle, the tailoring of the treatment to the alter-
ations present in the particular subgroup. Apart from
the tumour itself, the tumour stroma and the host are
also increasingly the focus of therapeutic approaches.
Antiangiogenic agents targeting the nutrient supply
of tumours have been in use for many years in GI
oncology. Recently, immuno-oncology has achieved
tremendous results – also in certain GI cancers. After
many years of searching for a master tumour antigen
the inhibition of immunological checkpoints is now at
the forefront of interest. Using so-called checkpoint inhi-
bitors targeting the programmed cell death protein
1/programmed death ligand-1 system, surprising results
could be achieved in subgroups of tumours, e.g. in colo-
rectal cancer with microsatellite instability. Here, almost
all heavily pretreated patients with metastatic colorectal
cancer achieved long-term survival when their tumour
exhibited this molecular feature. Consequently, this treat-
ment was approved for this subgroup by the Food and
Drug Administration and the European Medicines
Agency. Thus, there is very exciting progress in the field
and we are well on the road to a personalized treatment
of GI malignancies. There are of course unresolved issues
to tackle. First of all, not all tumours with a given muta-
tion respond to a specific targeted drug. Here we
need a better understanding of tumour heterogeneity.
Furthermore, we have to find ways to make immuno-
logically ‘cold’ tumours (alas, the majority of GI cancers)
accessible to the immune system.
Gastroesophageal reflux disease: Reducing
acid and complications, Rebecca Fitzgerald8
The widespread availability of proton pump inhibitor
(PPI) therapy has revolutionized the treatment of gas-
troesophageal reflux disease (GERD). This class of
drugs was first discovered in 1975 and in the 1980s
they were shown to be superior to H2 receptor antag-
onists. In 1996 Omeprazole became the world’s biggest
selling pharmaceutical and by 2004 over 800 million
patients had been treated worldwide.
For patients presenting to Gastroenterologists, diag-
nosis of reflux symptoms has become much more
sophisticated. Reflux and motility assessment has been
transformed by ambulatory pH tools including wireless
probes, multi-probe pH catheters, spectrophotometers to
detect bile reflux and impedance-pH monitoring, which is
currently considered to be the most accurate and detailed
method to assess gastroesophageal reflux. Patients can
now be sub-categorized into GERD, NERD (non-ero-
sive reflux disease) and reflux hypersensitivity, permitting
a more personalized treatment approach.
When required, anti-reflux surgery is largely
laparoscopic with a number of endoscopic modalities
available including magnetic sphincter augmentation
and transoral incisionless fundoplication.
In 2017 GERD presents a global economic burden.
The challenge is to ensure that PPIs are not over-used –
this is not only economically important but essential to
avoid long-term complications, particularly in the
elderly, and to ensure that patients are appropriately
investigated for complications such as pre-malignant
Barrett’s oesophagus.
Laparoscopic surgery: A diagnostic and
therapeutic success, Mario Morino9
In April 1989, Jacques Perissat presented at the Sages
Congress in Louisville the video of a laparoscopic
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cholecystectomy. K.A. Forde, Sages’ President, defined
that moment as ‘a singular event that changed the history
of surgery perhaps for all time.’ In the following years,
abdominal surgery was stormed by the so-called laparo-
scopic revolution: all abdominal surgical procedures were
performed by laparoscopy by an international group of
enthusiast minimal invasive surgeons.
The reason for such a huge success was the undeni-
able advantages of laparoscopy: reduced pain, quicker
recovery, shorter postoperative ileus, shorter hospital
stay, better cosmesis, and a better early quality of life.
These advantages were self-evident to every patient.
Randomized controlled trials were difficult to perform:
for some procedures such as cholecystectomy, fundo-
plication, Heller myotomy, bariatric, IBD resections,
adrenalectomy, splenectomy, etc. patients were reluc-
tant to accept randomization, favouring laparoscopic
access.
Oncologic digestive surgery was a different story.
The typical advantages of laparoscopy were related to
early postoperative courses; surgeons and oncologists
were sceptical of long-term results. But in the years
2000–2010 robust RCTs confirmed that laparoscopy
was superior to open surgery in terms of early clinical
results without affecting long-term disease-free survival
in colorectal cancer. These data prompted the diffusion
of oncological procedures: nowadays, laparoscopy
represents 50% of colorectal oncological surgery world-
wide, while hepatic resections, partial and total
gastrectomies and distal pancreatic resections are stead-
ily gaining popularity.
After 25 years of continuous advances in minimal
invasive surgery including robotics, transanal, 3D, etc.
we can affirm that the surgical trend towards a reduc-
tion in the trauma of surgical access represents one of
the major revolutions of surgery and will continue in
the near future as a consequence of technical, techno-
logical and clinical progress.
Watch the full recording of the session via UEGWeek
24/7. https://www.ueg.eu/anniversary-session-recording/
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